This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions
Generated Narrative: Evidence 293878
version: 8; Last updated: 2025-03-20 18:40:09+0000
Profile: InterventionOnlyEvidence
RelatesTo
- type: part-of
- targetReference: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)
url: https://fevir.net/resources/Evidence/293878
identifier: FEvIR Object Identifier/https://fevir.net/FOI/293878, outcomeId/313882, picoId/85789, sectionId/73212
name: Serious_hyperglycaemia_Intervention_Evidence_from_MAGICapp_313882
title: MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
status: Active
publisher: Computable Publishing LLC
contact: support@computablepublishing.com
author: Computable Publishing®: MAGIC-to-FEvIR Converter:
Code | Value[x] |
Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence Communication | InterventionOnlyEvidence |
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
description:
This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.
variableDefinition
description:
Adults with type 2 diabetes with moderate CV risk -- GLP-1 RA
variableRole: Population
observed: GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
variableDefinition
description:
Serious hyperglycaemia
variableRole: Outcome
observed: Serious hyperglycaemia
Description | StatisticType | Quantity |
Risk 1.0% | Proportion | 0.01 |